United States - English - NLM (National Library of Medicine)

edenbridge pharmaceuticals llc. - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide 0.5 mg - bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. almost equal diuretic response occurs after oral and parenteral administration of bumetanide. therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. bumetanide is contraindicated in anuria. although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide. bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the cond

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - amiloride hydrochloride dihydrate 5mg;  ; hydrochlorothiazide 50mg - tablet - 50mg/5mg - active: amiloride hydrochloride dihydrate 5mg   hydrochlorothiazide 50mg excipient: calcium hydrogen phosphate guar gum lactose magnesium stearate maize starch pregelatinised maize starch sunset yellow fcf - moduretic is indicated in the treatment of patients with: - oedema of cardiac origin; - hepatic cirrhosis with ascites; - hypertension in whom potassium depletion might be anticipated. moduretic, with its combination of amiloride hcl and hydrochlorothiazide, minimises the possibility of the development of excessive potassium loss in patients during vigorous diuresis for prolonged periods. moduretic, with its built-in potassium sparing agent, is especially indicated in those conditions where the positive effect on potassium balance is particularly important. moduretic may be used alone, or as an adjunct to other antihypertensive drugs. since it enhances the action of these agents, the dosage of these antihypertensive drugs may need to be reduced to avoid the risk of an excessive drop in blood pressure.

Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - bumetanide - tablet - bumetanide 1 mg - diuretics

United States - English - NLM (National Library of Medicine)

carilion materials management - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide 0.5 mg - bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. almost equal diuretic response occurs after oral and parenteral administration of bumetanide. therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. successful treatment with bumetanide following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. bumetanide is contraindicated in anuria. although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide. bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is

United States - English - NLM (National Library of Medicine)

hospira, inc. - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide 0.25 mg in 1 ml - bumetanide injection is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. almost equal diuretic response occurs after oral and parenteral administration of bumetanide. therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. successful treatment with bumetanide following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. bumetanide is contraindicated in anuria. although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide. bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition i

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide 2 mg - bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. almost equal diuretic response occurs after oral and parenteral administration of bumetanide. therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. bumetanide is contraindicated in anuria. although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide. bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the cond

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 50 mg; amiloride hydrochloride dihydrate, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; lactose monohydrate; magnesium stearate; povidone; wheat starch - amizide is indicated in the treatment of patients with: oedema of cardiac origin; hepatic cirrhosis with ascites; hypertension in whom potassium depletion might be anticipated. amizide, with its combination of amiloride hydrochloride and hydrochlorothiazide, minimizes the possibility of the development of excessive potassium loss in patients during vigorous diuresis for prolonged periods. amizide, with it's built in potassium sparing agent, is especially indicated in those conditions where the positive effect on potassium balance is particularly important. hypertension. amizide may be used alone or as an adjunct to other anti-hypertensive drugs. since it enhances the action of these agents, the dosage of these antihypertensive drugs may need to be reduced to avoid the risk of an excessive drop in blood pressure.

United States - English - NLM (National Library of Medicine)

cardinal health - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide 0.25 mg in 1 ml

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa inc - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide 0.5 mg

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide 0.5 mg